# Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

> **NCT02913417** · PHASE1,PHASE2 · UNKNOWN · sponsor: **David Minor, MD** · enrollment: 26 (estimated)

## Conditions studied

- Uveal Melanoma
- Hepatic Metastases

## Interventions

- **DEVICE:** SIR-Spheres® Yttrium 90
- **DRUG:** ipilimumab
- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT02913417
- **Lead sponsor:** David Minor, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10-10
- **Primary completion:** 2022-01
- **Final completion:** 2023-06
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2021-04-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02913417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02913417, "Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02913417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*